Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.
Haematologica
; 89(9): ECR30, 2004 Sep.
Article
en En
| MEDLINE
| ID: mdl-15377482
ABSTRACT
Pulmonary leukostasis is a rare but serious and often fatal complication of chronic myeloid leukemia (CML) in blast crisis and acute myeloid leukemia. Treatment options are limited for these patients. Imatinib mesylate (STI-571, Gleevec, Novartis) is a potent and selective inhibitor of the BCR-abl tyrosine kinase, the molecular abnormality that causes CML. The case of a 74-year-old man with a history of CML who presented in myeloid blast crisis with pulmonary leukostasis characterized by increasing dyspnea, hypoxemia, fever, and impending respiratory failure is reported. The patient was treated with single agent imatinib mesylate (IM) with rapid decrease in his white blood cell count (WBC) and marked improvement in his respiratory status. No electrolyte abnormalities consistent with tumor lysis syndrome were observed. IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Piperazinas
/
Pirimidinas
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Crisis Blástica
/
Leucostasis
/
Pulmón
/
Antineoplásicos
Tipo de estudio:
Etiology_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Haematologica
Año:
2004
Tipo del documento:
Article